<

SANOFI-AVENTIS (EPA:SAN) Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

Transparency directive : regulatory news

26/03/2022 15:00



Other stories

25/04/2024 21:52
25/04/2024 21:38
25/04/2024 22:43
24/04/2024 23:30
25/04/2024 23:14
25/04/2024 23:02
25/04/2024 12:32
25/04/2024 22:00
25/04/2024 22:50
25/04/2024 22:54
25/04/2024 18:42
25/04/2024 19:12
25/04/2024 18:37
25/04/2024 20:01
25/04/2024 18:59
25/04/2024 17:29
25/04/2024 12:17
25/04/2024 14:46
25/04/2024 22:55
25/04/2024 19:19
24/04/2024 09:00
25/04/2024 12:30
25/04/2024 20:24
25/04/2024 18:23
25/04/2024 18:02
25/04/2024 20:32
26/04/2024 01:00
25/04/2024 23:45
26/04/2024 00:52
25/04/2024 15:10
25/04/2024 14:18
25/04/2024 21:00
25/04/2024 19:30
25/04/2024 15:07
25/04/2024 06:00
25/04/2024 17:23
25/04/2024 23:38
25/04/2024 20:49